Astal Laboratories share price
BSE: 512600Pharmaceuticals & BiotechnologySmall Cap
ASTAL LABORATORIES LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 1994
Last close ₹61.70down ₹1.37 (2.17%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹63.07.
30 Oct: open ₹63.95, high ₹64.00, low ₹60.10
52-week range of traded prices to 30 Oct 2026
₹60.10Low, 30 Oct 2026₹100.00High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹270 Cr2,455th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.77
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 0.81
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 12,192
Results
Standalone, as consolidated accounts are on record for only 1 of the last ten years; ₹ crore.Astal Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +122.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +4.4%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹40 Crdown 3.43%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹3.71 Crup 241.37%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 9.4%
Revenue by quarter
Peak revenue ₹52 Cr, quarter to Dec 2025; lowest ₹13 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.2 | 14.5 | 23.5 | 25.3 | 37.5 | 52.2 | 40.9 | 39.5 |
| Net profit | 2.0 | 2.5 | 2.7 | 2.1 | 2.6 | 2.4 | 1.1 | 3.7 |
| Net margin | 15.2% | 17.2% | 11.7% | 8.3% | 6.9% | 4.5% | 2.7% | 9.4% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹156 Crup 142.87%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹8.12 Crdown 9.07%
- Net margin
- 5.2%
Revenue by year
Peak revenue ₹156 Cr, year to Mar 2026; lowest ₹0.00 Cr, year to Mar 2019
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 24 | 64 | 156 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 9 | 8 |
| Net margin | 1.6% | −2.3% | – | – | 3.0% | – | 0.5% | 3.3% | 13.9% | 5.2% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Astal Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 28% of 247 trading days over the last year.
LowestHighest
Its median32.07Industry median27.53
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −14.0% | −78.8% | +305.5% | 0.0% |
| 3 years | +30.2% | +260.3% | −63.9% | 0.0% |
| 5 years | +49.5% | +163.6% | −43.3% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Astal Laboratories insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group2 purchases, 0 sales₹0.36 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.36 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Astal Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Astal Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Medicamen BiotechMEDICAMEQ | 360 | – | 1.31 | +24.7% | – | – | 3.7% | 0.39% |
 Astonea LabsASTONEALAB | 357 | 79.15 | 6.26 | – | – | 12.0% | – | 0.00% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 339 | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Lyka LabsLYKALABS | 277 | – | 2.89 | +6.1% | −309.7% | −4.5% | −3.6% | 0.00% |
 Ambalal Sarabhai EnterprisesAMBALALSA | 268 | 19.78 | 1.69 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
 BDH IndustriesBDH | 240 | 20.49 | 3.12 | +44.8% | +22.9% | 16.1% | 18.2% | 1.20% |
 Zenotech LaboratoriesZENOTECH | 235 | – | 2.55 | −9.4% | – | −4.5% | −8.8% | 0.00% |
 Everest OrganicsEVERESTO | 234 | 44.49 | 3.10 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Astal Laboratories announcements
Sep 2026
30 Sep · Results
30 Sep · Meeting
30 Sep · Management
30 Sep · Management
29 Sep · Meeting
11 Sep · Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Astal Laboratories share price by year
Each calendar year to 2025.Astal Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 86.85 | +7.2% | 100.62 | 68.49 |
| 2024 | 81.00 | +129.3% | 129.15 | 35.33 |
| 2023 | 35.33 | +44.2% | 35.33 | 23.56 |
| 2022 | 24.50 | +195.2% | 30.05 | 7.25 |
| 2021 | 8.30 | −5.0% | 11.34 | 5.42 |
| 2020 | 8.74 | −4.9% | 9.19 | 8.74 |
| 2019 | 9.19 | 0.0% | 9.19 | 9.19 |
| 2018 | 9.19 | −39.5% | 14.45 | 9.19 |
| 2017 | 15.20 | −34.5% | 27.50 | 11.00 |
| 2016 | 23.20 | +5.5% | 31.65 | 15.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 12 Feb 2020. 2019 is from its first session, 1 Nov 2019. 2016 is from its first session, 20 Jul 2016. The close is the year's last trade for 2019 (1 Nov 2019) and 2018 (21 Nov 2018).
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 29 Oct 2026 | 66.10 | 66.10 | 62.68 | 63.07 | 64.60 | 12,255 |
| 28 Oct 2026 | 66.05 | 66.40 | 64.10 | 65.94 | 65.75 | 7,097 |
| 27 Oct 2026 | 66.95 | 67.95 | 66.00 | 66.85 | 66.31 | 3,382 |
| 26 Oct 2026 | 62.00 | 66.25 | 62.00 | 65.96 | 64.56 | 8,073 |
| 23 Oct 2026 | 67.50 | 67.83 | 62.01 | 63.81 | 63.06 | 13,208 |
| 22 Oct 2026 | 68.49 | 68.54 | 67.06 | 67.85 | 68.44 | 1,040 |
| 21 Oct 2026 | 67.90 | 71.00 | 66.15 | 67.21 | 68.65 | 15,016 |
| 19 Oct 2026 | 70.76 | 70.76 | 64.05 | 66.82 | 67.21 | 7,080 |
| 16 Oct 2026 | 67.00 | 70.00 | 66.50 | 69.14 | 68.88 | 6,754 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 512600
- ISIN
- INE307N01014
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.miel.co.in
- CIN
- L74120UP1993PLC015605
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1993
- Registered office
- Beetal House,, 3rd Floor,, 99 Madangir,, Behind Local Shopping Centre,, Nead Dada Harsukhdas Mandir, Plaza Kalpana, Ground Floor, 24/147, Brihana Road, Kanpur 208012, Uttar Pradesh
- Share registrar
- Beetal Financial & Computer Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments